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The glucokinase regulatory protein (GRP) plays a pivotal
role in the regulation of metabolic flux in liver by the
glucose-phosphorylating enzyme glucokinase. Random pep-
tide phage display library screening for binding partners of
GRP allowed the identification of an asparagine-leucine
consensus motif. Asparagine-leucine motifs of glucokinase
located in the hinge region, as well as in the large domain,
were changed by site-directed mutagenesis. The L58R/
N204Y and the L309R/N313Y glucokinase mutants showed a
significantly reduced interaction with GRP. The L355R/
N350Y mutant had a fivefold-higher binding affinity for
GRP than wild-type glucokinase. Imaging of glucokinase
and GRP fluorescence fusion proteins revealed that the
L58R/N204Y glucokinase mutant lacked glucose-dependent
translocation by GRP, whereas the L355R/N350Y glucoki-
nase mutant was trapped in the nucleus due to high affinity
for GRP. The results indicate that the L58/N204 motif in
the hinge region confers binding to GRP, while the L355/
N350 motif may modulate the binding affinity for GRP. This
latter motif is part of the 10 helix of glucokinase and
accessible to GRP in the free and complex conformation.
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T
he glucose phosphorylating enzyme glucokinase
regulates glycolytic flux at physiological millimo-
lar glucose concentrations in liver and pancre-
atic -cells (1–4). Glucokinase (hexokinase type
IV; EC 2.7.1.2) has specific kinetic properties different
from those of the other mammalian hexokinases (5). The
enzyme shows a sigmoidal saturation curve and a low
affinity for glucose. Furthermore glucokinase is not inhib-
ited by its product glucose-6-phosphate. In addition to
transcriptional mechanisms, hepatic glucokinase enzyme
activity is modulated on the posttranslational level
through an interaction with a regulatory protein (6–9).
This glucokinase regulatory protein (GRP) is expressed
mainly in hepatocytes, although there is also evidence for
an expression in the hypothalamus (10). GRP inhibits
glucokinase in a competitive manner with respect to the
substrate glucose. Glucokinase inhibition by GRP is stim-
ulated by fructose-6-phosphate and suppressed by fruc-
tose-1-phosphate. Both phosphate esters bind to a specific
site of the GRP (11). Recent studies provide evidence for
species-specific regulatory properties of fructose phos-
phates with respect to the inhibition of glucokinase by
GRP (12). In mammalian hepatocytes, glucokinase is
bound to the GRP and mainly localized in the nucleus at
basal low-glucose concentrations. At increased glucose
concentrations or in the presence of fructose, glucokinase
rapidly translocates from the nucleus to the cytoplasm
(13–19). Experiments with nonhepatic cellular models
have clearly shown that GRP is required for the intracel-
lular shuttling of glucokinase into the nucleus (20–22).
Previously, the amino acid residues V203 and N204, as
well as the clusters formed by E52 and H141, K142, K143,
and L144 in the glucokinase sequence, have been de-
scribed to mediate the binding to GRP (23–25). These data
implicated a model in which the tip of the small domain
and the hinge region were involved in the interaction with
GRP. Another study with glucokinase-hexokinase chime-
ras postulated a large interface in the glucokinase protein
for GRP binding (22). Using a phage display library screen-
ing, we recently identified a binding motif within the GRP
that is crucial for the interaction with the glucokinase
protein (26). The aim of our present work was, therefore,
using the same approach, to identify the corresponding
glucokinase-binding motif for the interaction with the
GRP. The experiments revealed an asparagine-leucine
consensus–binding motif, which could be found in differ-
ent areas of the glucokinase protein. Studies using glucoki-
nase mutant proteins showed that this motif is of crucial
importance for the interaction of glucokinase with the
GRP and the cytoplasmic-nuclear distribution of glucoki-
nase in hepatocytes.
RESEARCH DESIGN AND METHODS
Hybond N nylon membranes were obtained from Amersham (Braunschweig,
Germany). The enhanced chemiluminescence detection system and autora-
diography films were from Amersham Pharmacia Biotech (Freiburg, Ger-
many). Restriction enzymes and modifying enzymes for the cloning
procedures were from New England Biolabs (Beverly, MA) or Fermentas
(Fermentas, St. Leo-Rot, Germany). Custom oligonucleotides were synthe-
sized by Gibco (Karlsruhe, Germany) or MWG Biotech (Ebersberg, Germany).
Media and supplements for culture of yeast were from Clontech (Palo Alto,
CA). Columns for DNA purification were from Qiagen (Hilden, Germany).
Collagenase H was from Roche (Penzberg, Germany) and collagen type I from
rat tail from Sigma (Taufkirchen, Germany). All other reagents of analytical
grade were from Merck (Darmstadt, Germany).
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Generation of the glucokinase mutants. Site-directed mutagenesis of
-cell glucokinase cDNA was performed as previously described (27). The
sequences of the specific mismatch oligonucleotides for mutagenesis are
shown in Table 1 and refer to human islet glucokinase (GenBank M90299)
(28). All glucokinase mutations were verified by sequence analysis.
Expression and purification of recombinant proteins. The full coding
sequences of rat liver GRP, wild-type glucokinase, and glucokinase mutants
were subcloned in frame into the BamHI and SalI sites of the pGEX-6P-1
expression vector and expressed by the glutathione S-transferase (GST) Gene
Fusion System in E. coli BL21 (Amersham Pharmacia Biotech, Freiburg,
Germany). The GST-tag was cleaved by incubation with PreScission protease.
Recombinant proteins were verified using PAGE and Western blot analysis as
previously described (29). The eluted proteins were stabilized by 50% glycerol
and stored at 20°C.
Immobilization of recombinant liver GRP. The recombinant rat liver GRP
was immobilized by the GST-tag on Reacti-Bind glutathione-coated microplate
strips (Pierce, Rockford, IL). Two-hundred microliters of the protein solution
(200 ng/ml GRP in 0.1 mol/l NaHCO3) were incubated overnight at 4°C with
gentle agitation in the microplate wells. Thereafter, the supernatant was
removed and the wells blocked with 300 l blocking buffer (5 mg/ml BSA in
0.1 mol/l NaHCO3) for 1 h at 4°C with gentle agitation.
Phage display screening. The selection of peptides able to bind to the GRP
was performed with the Ph.D.-12 Phage Display Peptide Library (New England
Biolabs) according to the manufacturer’s instructions. Specifically bound
phages were eluted with glycine buffer and the recovered phages amplified in
ER2537 E. coli bacteria. The variable region was characterized by sequence
analyses. The phage enzyme-linked immunosorbent assay (ELISA) experi-
ments for quantification of binding affinity were performed as previously
described (26). Samples of 1014 phages per well were analyzed for the
interaction with the GRP.
Yeast two-hybrid analysis. Yeast two-hybrid analysis was performed with
the Matchmaker GAL4 system 2 (Clontech) as described in the manufacturer’s
manual. The coding cDNA sequences of the -cell wild-type and mutant
glucokinase proteins were subcloned in frame (SmaI and BamHI restriction
sites) to the activation domain into pACT2. Rat liver GRP coding cDNA was
subcloned in frame (NcoI and EcoRI restriction sites) to the binding domain
into pAS2–1. All constructs were verified by sequence analyses. Yeast S.
cerevisiae strain CG1945 or Y190 (Clontech) was transfected with the
appropriate pAS2–1 and pACT2 plasmids by using the lithium acetate proce-
dure and grown on SD agar plates without leucine and tryptophan. The
quantitative chemiluminescent -galactosidase assay of yeast two-hybrid
interaction was performed as previously described (26).
Assay of glucokinase enzyme activity. Glucokinase enzyme activities were
measured by an enzyme-coupled photometric assay (27,30,31). For each
glucokinase mutant protein, three experiments were done in triplicate.
Enzyme activities were expressed as units per milligram of purified glucoki-
nase protein. One unit of enzyme activity was defined as 1 mol glucose-6-
phosphate formed from glucose and ATP per min at 37°C (30). The Km values
and Hill coefficients of glucokinase were calculated from Hill plots (32).
Western blot analyses. Cells were homogenized by sonication in PBS (pH
7.4), and insoluble material was pelleted by centrifugation. Cellular protein
(10 g) was fractionated by reducing 10% SDS-PAGE and electroblotted to
polyvinylidine difluoride membranes. The membranes were stained by Pon-
ceau to verify the transfer of comparable amounts of cellular protein.
Glucokinase immunodetection was performed as previously described (29).
For GRP, the blots were incubated with a GRP antibody (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA) at a dilution of 1:500, followed by a 4-h
incubation period with an anti-goat IgG peroxidase-labeled secondary anti-
body at a dilution of 1:20,000 at room temperature. The specific protein bands
were visualized by chemiluminescence using the enhanced chemilumines-
cence detection system.
Construction of pECFP-C1, pEYFP-C1, and pEYFP-N1 fusion vectors. The
cDNAs of -cell glucokinase wild-type and mutant proteins were subcloned in
frame (SmaI and BamHI restriction sites) to both the enhanced cyan
TABLE 2
Sequences of GRP-binding peptides selected from a M13 phage display library
The sequences of peptides displayed by GRP-binding phages were identified through a selection protocol consisting of three rounds of
high-stringency panning from a 12-mer random peitide M13 phage display library. This procedure revealed the N-(X)n-L consensus motif
consisting of an asparagine (N) and leucine (L) residue that were separated by three to five amino acids.
TABLE 1






Mutagenesis oligonucleotide (localization in
glucokinase cDNA sequence)
Single mutations
L58R Leu Arg 5-AGT GTG AAG ATG CGG CCC ACC TAC GTG-3 (618–644)
N204Y Asn Tyr 5-GTG GCA ATG GTG TAT GAC ACG GTG GCC-3 (1056–1082)
L309R Leu Arg 5-GTG CTG CTC AGG CGC GTG GAC GAA AAC-3 (1371–1397)
N313Y Asn Tyr 5-CTC GTG GAC GAA TAC CTG CTC TTC CAC-3 (1383–1409)
N350Y Asn Tyr 5-AAG CAG ATC TAC TAC ATC CTG AGC ACG-3 (1494–1520)
L355R Leu Arg 5-ATC CTG AGC ACG CGG GGG CTG CGA CCC-3 (1509–1535)
Double mutations
L58R/N204Y Leu/Asn Arg/Tyr 5-AGT GTG AAG ATG CGG CCC ACC TAC GTG-3 (618–644)
5-GTG GCA ATG GTG TAT GAC ACG GTG GCC-3 (1056–1082)
L309R/N313Y Leu/Asn Arg/Tyr 5-GTG CTG CTC AGG CGC GTG GAC GAA TAC CTG CTC TTC CAC-3 (1371–1409)
N350Y/L355R Asn/Leu Tyr/Arg 5-AAG CAG ATC TAC TAC ATC CTG AGC ACG CGG GGG CTG CGA CCC-3 (1494–1535)
Mutated nucleotides are bold and underlined.
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fluorescent protein (ECFP) into pECFP-C1 and the enhanced yellow fluores-
cent protein (EYFP) into pEYFP-C1 (Clontech). Rat liver GRP coding cDNA
was subcloned in frame (BglII and EcoRI restriction sites) to the EYFP into
pEYFP-N1. All constructs were verified by sequence analyses.
Cell culture and transient transfection of COS-1 cells. COS-1 cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with 25 mmol/l
glucose and 10% (vol/vol) FCS in a humidified atmosphere at 37°C and 5% CO2.
Cells were seeded at a density of 2  104 cells on three glass cover slips stored
in a 35-mm dish, and transfection was performed the day thereafter with 1 g
plasmid DNA and 2 l jetPEI (Qbiogene, Montreal, Canada) according to the
manufacturer’s instructions. Cells were cultured for 24 h, and thereafter
coverslips were incubated in Dulbecco’s modified Eagle’s medium with either
5.5 or 25 mmol/l glucose for an additional 3 h.
Hepatocyte isolation, culture, and transient transfection. Primary hepa-
tocytes were isolated from fed Wistar rats (150–200 g) using a modification of
the collagenase perifusion method of Seglen (33) and Bader et al. (34).
Isolated cells were suspended in Williams’ medium E supplemented with 10
mmol/l glucose, 5% (vol/vol) FCS, 104 mmol/l dexamethasone, and 105
mmol/l insulin. Cell viability tested by trypan blue staining was at least 80%.
Thereafter, hepatocytes were seeded at a density of 5  105 cells on three
collagen type I–coated glass cover slips, stored in a 35-mm dish, and
incubated in a humidified atmosphere at 37°C and 5% CO2. After 3 h, the
nonadherent cells were removed and attached cells transfected with 2 g
plasmid DNA and 6 l jetPEI-Gal (Qbiogene) according to the manufacturer’s
instructions. Hepatocytes were cultured for 24 h, and thereafter cover slips
were incubated in Williams’ medium E with either 5 or 20 mmol/l glucose for
an additional 3 h.
Fluorescence microscopy, image acquisition, and deconvolution. Cover
slips were mounted in a custom-made chamber. The thermostatically con-
trolled (37°C) chamber was filled with 200 l of the appropriate medium and
fixed on the stage of an Olympus IX81 inverted microscope (Olympus Optical,
Tokyo, Japan) equipped with a PLAPO 60  1.4–NA oil-immersion objective
(Olympus) and a YFP/CFP dual-band beamsplitter and emitter (AHF Anal-
ysentechnik, Tübingen, Germany). Alternate EYFP and ECFP excitation light
with adjusted intensity was injected from the cellR MT20 illumination system
(Olympus BioSystems, Planegg, Germany) using HQ 500/20 and D 436/10
filters (AHF Analysentechnik). Images were taken with a charge-coupled
device camera (6.45  6.45–m pixels; Olympus BioSystems). System syn-
chronization and multidimensional image acquisition during the experiment
were controlled with cellR hardware and software (Olympus BioSystems).
EYFP/ECFP double-color images were removed from bleed-through artifacts
by cellR spectral unmixing. Deconvolution and image analysis were performed
using AutoDeblur 9.3 WF software (Autoquant Imaging, Watervliet, NY).
Statistical analyses. Data are expressed as means  SE. Statistical analyses
were performed by ANOVA followed by Bonferroni’s or Dunnett’s test for
multiple comparisons using the Prism analysis program (Graphpad, San
Diego, CA).
RESULTS
Isolation of GRP-binding phages. To identify GRP-
binding motif(s) within the glucokinase, a systematic
screening of recombinant rat liver GRP was performed
with a 12-mer random peptide M13 phage display library. A
control experiment using immobilized GST protein was
performed in order to exclude sequences that only bind to
the GST-tag. The selected specific GRP-binding dode-
capeptides showed a strong enrichment of the amino acid
asparagine (Table 2). In comparison to the control exper-
iment with scrambled peptides, the relative frequency of
asparagine within the dodecapeptides increased fourfold
(data not shown). Notably, the asparagine-containing pep-
tide sequences also comprised a leucine residue separated
from the asparagine by three to five amino acids in 15
clones (Table 2). This consensus sequence could not be
detected in dodecapeptides isolated from the GST-control
panning. Thereafter, the binding affinity of the isolated
consensus peptide–displaying phages was verified through
an ELISA-binding assay. Randomly amplified peptide
phages of the original library were used as control. Pep-
tides with the asparagine-leucine motif exhibited a high
binding affinity to GRP that was significantly different from
the control level of the GST (Fig. 1).
Localization of the GRP-binding motif in the glucoki-
nase protein. The amino acid sequence of human glucoki-
nase was screened for the residue asparagine alone and
FIG. 1. Characterization of the GRP-binding affinity of consensus
peptide–displaying phages by ELISA. Binding affinities of consensus
peptide–displaying phages and control peptide phages to GST-GRP–
coated (f, GRP) and GST-coated (, GST) microplate wells were
detected by ELISA. The A405 values are means  SE from three
independent experiments. *P < 0.05 vs. GST-coated wells (ANOVA/
Bonferroni’s test).
FIG. 2. Localization of asparagine-leucine motifs for GRP binding
within the glucokinase protein. Glucokinase structure coordinates of
the inactive “free” (A, C, and E) and active “complex” (B, D, and F)
conformation of the enzyme protein were obtained from the RCSB
Protein Data Bank (36). The proposed GRP-binding motif L58/N204 is
depicted in A and B, the motif L309/N313 in C and D, and the motif
N350/L355 in E and F. The structural glucokinase models were gener-
ated using the Vector NTI Suite program 3D Molecule Viewer (Infor-
Max, Bethesda, MD).
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the identified asparagine-leucine–binding motif. Within
the whole glucokinase molecule consisting of 465 amino
acids, the hydrophilic residue asparagine appeared 12
times; 4 of these occurrences (N83/L88, N283/L288, N350/
L355, and L386/N391) were part of an asparagine-leucine
motif. In addition, asparagine and leucine were neighbor-
ing amino acids (L164-L165-N166) or appeared in a com-
plex structure (N179-N180/L184-L185). Because these
motifs were not detected by our systematic phage display
approach, we excluded these sequences from further
analyses. In the glucokinase model, the asparagine N313
was surrounded by several leucines (L301, L304, L306,
L307, L309, L314, and L315) and could therefore form a
possible GRP-binding structure. Both the three-dimen-
sional model created on the basis of the crystal structure
of yeast hexokinase B (35) and the recently described
crystal structures of the “complex” (active) and “free”
(inactive) glucokinase conformations (36) proved to be
helpful for the localization of the putative GRP-binding
motifs. From the possible asparagine-leucine motifs in the
glucokinase protein sequence, only the amino acids N350
and L355 appeared in the “free” (Fig. 2E), as well as in the
“complex” tertiary structure as a putative binding anchor
of GRP (Fig. 2F). Interestingly, the leucine of this motif is
part of a postulated glucokinase nuclear export signal
(22). A second proposed nuclear export signal contained
leucine L309 (22), which is separated by three amino acids
from the asparagine N313. The L309/N313 motif was
presented for interaction with GRP in the “free” (Fig. 2C)
rather than the “complex” (Fig. 2D) conformation of
glucokinase. This asparagine-leucine motif, as well as the
N350/L355 sequence, is located in the COOH-terminal lobe
of the glucokinase protein.
Screening the asparagines in the tertiary structure of the
glucokinase enzyme, the N204 residue also yielded a
remarkable spatial vicinity to the L58 residue in the
catalytic cleft in the “free” conformation of the enzyme
(Fig. 2A). The asparagine N204 is localized in the hinge
region, and in previous studies this residue has been
implicated in the binding of the GRP (25). N204 is also part
of the glucose-binding side of glucokinase, and therefore
the putative binding anchor L58/N204 is lost in the active
conformation (Fig. 2B).
To elucidate which putative asparagine-leucine glucoki-
nase–binding sequences are involved in the interaction
with the GRP, a series of six single and three double
mutations were generated by site-directed mutagenesis. In
the mutant glucokinase proteins, the aliphatic nonpolar
amino acid leucine (L) was systematically replaced by the
strongly basic residue arginine (R) and the hydrophilic
amide asparagine (N) by the hydrophobic aromatic amino
acid tyrosine (Y).
Yeast two-hybrid interactions of GRP with wild-type
and mutant glucokinase protein. To study the interac-
tion of the glucokinase mutant proteins with the GRP, the
glucokinase cDNA and the mutated glucokinase cDNAs
were subcloned into vectors of the GAL4 system. Protein
expression of wild-type and mutant glucokinase was con-
firmed by Western blot analyses (data not shown). Control
experiments excluded nonspecific interactions of the pro-
teins with the truncated activation and binding domains of
the vectors (data not shown). Experiments were per-
formed in the yeast host strain Y190, and protein interac-
tions were quantified by the -galactosidase reporter
enzyme. The wild-type glucokinase showed a strong bind-
ing to the GRP with a 10-fold increase of the reporter gene
activity compared with background activity by the trun-
cated binding domain interaction (Fig. 3A).
The double mutation L58R/N204Y (Fig. 3A) and the
single mutations L58R and N204Y (Fig. 3B) in the glucoki-
nase protein significantly decreased the binding affinity to
the GRP by a factor of 10, 7, and 12, respectively. The
double mutation L309R/N313Y of the glucokinase protein
showed only a twofold decrease of reporter gene activity
in comparison to the wild-type glucokinase protein (Fig.
3A). Experiments performed with glucokinase mutants
where only amino acid L309 or amino acid N313 was
changed resulted in opposite effects. While a significant
decrease to the background values was observed with the
L309R mutant, the single mutation N313Y resulted in a
fourfold increase of reporter gene activity (Fig. 3B). In
contrast, the N350Y/L355R glucokinase mutant showed a
strongly increased binding to the GRP, with a fivefold-
higher reporter gene activity than wild-type glucokinase
(Fig. 3A). The two corresponding single mutations N350Y
and L355R also increased the reporter gene activity by a
factor of three in both cases (Fig. 3B).
The same two-hybrid results were obtained for all
FIG. 3. Yeast two-hybrid interactions of wild-type (WT) and mutant
glucokinase proteins with the GRP. Full-length cDNAs of human -cell
glucokinase wild-type and mutant proteins (L58R, N204Y, L309R,
N313Y, N350Y, L355R, L58R/N204Y, L309R/N313Y, and N350Y/L355R)
were cloned as fusion proteins together with the activation domain
(AD) of the GAL4 yeast two-hybrid system. The rat liver GRP was fused
to the binding domain (BD). Yeast two-hybrid interactions were quan-
tified by a chemiluminescent -galactosidase reporter gene assay from
yeast extracts. Shown are means  SE from five independent experi-
ments. Double-mutant proteins are shown in A (*P < 0.05 vs. back-
ground activity of wild-type glucokinase fused to the activation domain
and a binding domain without fusion partner; #P < 0.05, ##P < 0.01 vs.
interaction between GRP and wild-type glucokinase). Single-mutant
glucokinase proteins are shown in B (*P < 0.05, **P < 0.01 vs. binding
activity between GRP and wild-type glucokinase [ANOVA/Bonferroni’s
test]).
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mutants when the glucokinase-GRP interactions were
evaluated semiquantitatively through activation of the
HIS3 reporter gene in the yeast strain CG1945 and growth
selection on SD agar plates lacking leucine, tryptophan,
and histidine for 5 days after plating (data not shown).
Kinetic properties of recombinant wild-type and mu-
tant glucokinase proteins. All glucokinase proteins ex-
hibited a molecular weight of 52 kDa, which was
comparable to that of the wild-type glucokinase protein
(data not shown). Sufficient amounts of glucokinase pro-
tein for kinetic analysis could be obtained for the glucoki-
nase mutants L58R, N204Y, N313Y, N350Y, L58R/N204Y,
and N350Y/L355R. Recombinant wild-type human glucoki-
nase protein showed a Vmax value of 35.0  0.5 units/mg
protein, an S0.5 value of 6.2  0.3 mmol/l, and a Hill
coefficient of 1.6  0.1 for glucose. In enzyme activity
studies, the double-mutant glucokinase protein L58R/
N204Y, as well as the single-mutant proteins L58R and
N204Y, showed a complete loss of glucokinase activity. All
other glucokinase mutations showed only slight differences
in comparison to the wild-type protein. The N313Y mutation
resulted in a significant increase of the Vmax value to 40.1 
0.6 units/mg protein and an S0.5 value of 9.3  0.3 mmol/l for
glucose, while the Hill coefficient (1.6  0.1) was not affected.
The single-mutation N350Y decreased the Vmax for the sub-
strate glucose (26.0  0.3 units/mg protein), while both the
S0.5 value (6.5  0.2 mmol/l) and the Hill coefficient (1.4 
0.1) were not different from wild-type glucokinase. The
double-mutation N350Y/L355R also showed a significant de-
crease of the Vmax value with 29.0  0.4 units/mg protein but
showed an increase in the S0.5 value with 7.3  0.3 mmol/l.
The Hill coefficient (1.6  0.1) was not changed in compari-
son to the wild-type protein.
Subcellular localization of wild-type and mutant glu-
cokinase proteins in COS-1 cells and primary hepa-
tocytes. To investigate the subcellular localization of the
mutant glucokinase proteins compared with wild type,
FIG. 4. Effects of 5.5 or 25 mmol/l glucose on the localization of EYFP-GRP, wild-type (WT) ECFP-glucokinase (GK), and mutant ECFP-
glucokinase in COS-1 cells. A: COS-1 cells were transfected with EYFP-GRP and wild-type or mutant ECFP-glucokinase (L58R/N204Y,
L309R/N313Y, and N350Y/L355R). B: COS-1 cells were transfected with EYFP-GRP and mutant ECFP-glucokinase (L58R, N204Y, L309R, N313Y,
N350Y, and L355R). Fluorescence images were taken after a 3-h incubation period at 5.5 or 25 mmol/l glucose. In the merged images, EYFP is
depicted in red and ECFP in green. The depicted fluorescence images were obtained from z-stacks after deconvolution and are representative of
four cells each in five independent experiments. Scale bar, 20 m.
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fusion proteins were generated with EYFP and ECFP. For
live-cell imaging of the fluorescence proteins, COS-1 cells
were used as an established cellular model, which neither
expressed glucokinase nor GRP (20). Protein expression
in transfected COS-1 cells was confirmed by Western blot
analysis (data not shown). While transient transfection of
EYFP resulted in a uniform cellular distribution of the
fluorescence protein, the EYFP-glucokinase construct was
exclusively located in the cytoplasm. None of the glucoki-
nase mutants showed a difference in comparison to the
cytoplasmic distribution of wild-type glucokinase. EYFP-
GRP was predominantly localized in the nucleus of COS-1
cells, although a weak expression was also detectable in
the cytoplasm (data not shown).
In COS-1 cells cotransfected with ECFP-glucokinase
and EYFP-GRP, the glucokinase protein was localized in
the nucleus together with GRP at 5.5 mmol/l glucose (Fig.
4A). At 25 mmol/l glucose, glucokinase was predominantly
detectable in the cytoplasm, while GRP was located in the
nucleus (Fig. 4A). In contrast, the mutant glucokinase
proteins L58R/N204Y and L309R/N313Y were located in
the cytoplasm at both 5.5 and 25 mmol/l glucose (Fig. 4A).
The ECFP-N350Y/L355R glucokinase mutant showed a
distinct fluorescence in the nucleus at low and high
glucose concentrations (Fig. 4A). This was demonstrated
by a high nuclear-to-cytoplasmic glucokinase ratio of 2.0 at
25 mmol/l glucose compared with 0.7 for the wild type
(Table 3). The single-mutant glucokinase proteins L58R,
N204Y, and L309R showed a cytoplasmic localization
irrespective of the glucose concentration (Fig. 4B and
Table 3). The subcellular localization of the glucokinase
mutants N313Y, N350Y, and L355R was comparable to that
of the wild-type glucokinase protein (Fig. 4B and Table 3).
Primary rat hepatocytes were transfected with EYFP
constructs for further analyses of the glucokinase mutant
proteins. The protein expression level of the endogenous
GRP and the wild-type or mutant glucokinase was con-
firmed by Western blot analysis (data not shown). Wild-type
EYFP-glucokinase was predominantly in the hepatocyte nu-
cleus at 5 mmol/l glucose, as demonstrated by a high nuclear-
to-cytoplasmic glucokinase ratio of 2.3, whereas a uniform
cellular distribution was detectable at 20 mmol/l glucose
with a nuclear-to-cytoplasmic glucokinase ratio of 1.4 (Fig.
5). The glucokinase double-mutant L58R/N204Y was found
exclusively in the cytoplasm at both high and low glucose
concentrations (Fig. 5). The nuclear-to-cytoplasmic glu-
cokinase ratio was significantly lower for the mutant
L58R/N204Y and the mutant L309R/N313Y when compared
with the wild-type protein (Fig. 5). In contrast to L58R/
N204Y, the L309R/N313Y glucokinase mutant was clearly
visible in the nucleus at 5 mmol/l glucose (Fig. 5). The
N350Y/L355R glucokinase mutant showed a significantly
increased nuclear-to-cytoplasmic glucokinase ratio both at
5 and 20 mmol/l glucose (Fig. 5).
FIG. 5. Different subcellular distribution of wild-type (WT) EYFP-
glucokinase (GK), L58R/N204Y, L309R/N313Y, and N350Y/L355R mu-
tant EYFP-glucokinase in primary rat hepatocytes. A: Rat hepatocytes
were transfected with EYFP-glucokinase wild-type or mutant EYFP-
glucokinase (L58R/N204Y, L309R/N313Y, and N350Y/L355R). Fluores-
cence images were taken after incubation with 5 (images 1, 3, 5, and 7)
or 20 (images 2, 4, 6, 8) mmol/l glucose for 3 h. Each panel shows an xz
image of the line marked in the xy image. The nuclear region in the xz
image is marked by a red arrow. The depicted fluorescence images were
obtained from z-stacks after deconvolution and are representative of
three independent experiments. Scale bar, 20 m. B: The nuclear-to-
cytoplasmatic fluorescence intensity ratio was calculated from 20
nuclear and 20 cytoplasmic pixel measurements (cellR software; Olym-
pus BioSystems) of each image. Shown are means  SE of three
independent experiments. *P < 0.05, ***P < 0.001 vs. wild-type
glucokinase at 5 mmol/l glucose (f); ##P < 0.01 vs. wild-type glucoki-
nase at 20 mmol/l glucose ().
TABLE 3
Nuclear-to-cytoplasmic glucokinase ratio in COS-1 cells trans-





Wild type 2.5  0.5 0.7  0.1
Single mutant
L58R 0.8  0.1* 1.0  0.1
N204Y 1.0  0.1* 0.9  0.1
L309R 1.0  0.3* 0.8  0.1
L313Y 1.9  0.3 0.8  0.1
N350Y 1.7  0.2 1.0  0.1
L355R 2.5  0.2 0.7  0.1
Double mutant
L584R/N204Y 0.8  0.1* 0.8  0.1
L309R/N313Y 0.7  0.1* 0.7  0.1
L350Y/L355R 3.1  0.2 2.0  0.2*
COS-1 cells were transfected with EYFP-GRP and wild-type or
mutant ECFP-GK. The nuclear-to-cytoplasmatic flucorescence inten-
sity ratio was calculated from 20 nuclear and 20 cytoplasmic pixel
measurements (cellR software; Olympus BioSystems) of each image.
Nuclear-to-cytoplasmic glucokinase ratios were calculated from four
cells each in five independent experiments. *P  0.01 vs. wild-type
glucokinase at the same glucose concentration (ANOVA/Dunnett’s
multiple comparison test).
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DISCUSSION
Posttranslational regulation of glucokinase in liver is cru-
cially dependent upon the interaction with the regulatory
protein (GRP) (15). It was therefore the aim of this study
to identify potential binding motifs of GRP within the
glucokinase protein by a systematic peptide phage display
methodology. Using this strategy, we obtained peptides
with an asparagine-leucine motif, which showed a high
affinity to the GRP in continuative ELISAs. At first, we
analyzed the glucokinase structure for localization of
asparagine-leucine motifs as a possible binding anchor for
GRP. An asparagine-leucine motif exists four times (N83/
L88, N283/L288, N350/L355, and L386/N391) in the glucoki-
nase protein, of which only the amino acids N350 and L355
are presented in a sterically accessible localization (36). In
addition, a sequence alignment for the hexokinase family
revealed that the asparagine N350 exists exclusively in the
glucokinase sequence (37), whereas N83, N283, and N391
also could be found in high-affinity hexokinase isoen-
zymes. The analysis of the tertiary structure of glucoki-
nase showed that a spatial vicinity of the amino acids
asparagine and leucine was obvious for L164-L165-N166
and N179-N180/L184-L185, in which only the latter group
completely corresponded to the characteristics of the
consensus epitope. Previous studies of mutated glucoki-
nase proteins provided evidence for a participation of
asparagine N166 and N180 in the binding to GRP (23,25).
Both amino acid residues are located between the smaller
domain and the hinge region of glucokinase, which essen-
tially determines the cooperativity of the enzyme. But the
mutation of the residues N166 to arginine and N180 to
aspartic acid was less effective with respect to the inter-
action properties to the GRP. Furthermore, the asparagine
N313 was studied because this residue is surrounded by
several leucines with L309 as part of a postulated glucoki-
nase nuclear export signal (22). Finally, the analysis of the
tertiary glucokinase structure revealed a close spatial
vicinity of L58 and N204 on the surface of the glucokinase
hinge region. The glucokinase residue N204, which is
highly conserved within the hexokinase family, is part of
the glucose-binding site and also mediates the binding to
GRP (21,25,35,36,38).
In agreement with previous studies, the glucokinase
mutant N204Y showed a loss of GRP-binding affinity and of
intrinsic glucokinase activity (21,25). Comparable results
also were obtained for the glucokinase mutants L58R and
L58R/N204Y. Notably, the L58R/N204Y glucokinase double
mutant was exclusively expressed in the cytoplasm irre-
spective of the glucose concentration in both GRP-over-
expressing COS-1 cells and primary hepatocytes. These
results correspond to the loss of GRP binding determined
in the yeast two-hybrid–binding assay. While N204 has
been described to play an important role for glucose
binding, the amino acid L58 thus far has not been consid-
ered to participate in the formation of the catalytic pocket
of glucokinase. Interestingly, the spatial vicinity of N204
and L58 is apparent only in the super-open conformation,
but not the closed conformation, of glucokinase (36).
Through replacement of L58 by the basic amino acid
residue arginine, we potentially induced a change in the
glucokinase conformation that may significantly affect the
transition between the active and inactive state of the
enzyme. Therefore, both the intrinsic glucose phosphory-
lation activity and the GRP-binding affinity were nearly
completely abolished in the L58R glucokinase mutant.
However, these data also indicate that the conformation of
the glucokinase hinge region in the super-open form and,
in particular, the L58/N204 motif are of crucial importance
for the interaction with GRP.
In hepatocytes, the L309R/N313Y glucokinase mutant
showed a significantly lower presence in the nucleus than
the wild-type glucokinase at both low and high glucose
concentrations, but interestingly, the nuclear-to-cytoplas-
mic glucokinase ratio was higher than in the case of
mutant L58R/N204Y at 5 mmol/l glucose. Thus, glucoki-
nase translocation in hepatocytes reflects the higher GRP-
binding affinity of the L309R/N313Y glucokinase mutant in
the yeast two-hybrid–binding assay when compared with
mutant L58R/N204Y. Surprisingly, the single-mutation
N313Y resulted in a protein with a higher binding affinity to
GRP than that of wild-type glucokinase. A significantly
higher intrinsic activity than the wild-type protein was also
observed with this mutant. However, in comparison with
naturally occurring glucokinase mutations inducing a hy-
poglycemic syndrome, the increase of enzyme activity of
the N313Y mutant was less impressive (39,40). The L309R
glucokinase mutant showed a loss of GRP binding in yeast
two-hybrid studies and of nuclear localization in COS-1
cells. Notably, the L309 residue is part of a leucine-rich
region from glucokinase amino acids 300–310, which was
postulated to represent a nuclear export signal for glucoki-
nase (22). A L306A/L307A/L309A mutant glucokinase frag-
ment comprising amino acids 299–359 showed a higher
nuclear-to-cytoplasmic glucokinase ratio compared with
the wild-type sequence after transfection as a green fluo-
rescent protein fusion protein in HeLa cells (22). However,
the existence of a glucokinase nuclear export signal
remains open because nuclear export of glucokinase was
not inhibited by leptomycin B (41). Our present data
obtained with the L309R glucokinase mutant holoenzyme
indicate a block of nuclear import by the GRP but do not
allow us to conclude that this residue has a functional role
in nuclear export.
The GRP-binding affinity of glucokinase mutants N350Y
and L355R increased by a factor of 3 and that of the
double-mutant N350Y/L355R by a factor of 5 in compari-
son to the wild-type glucokinase. Thus, the mutation of the
whole asparagine-leucine motif resulted in a significantly
FIG. 6. Structures of human glucokinase and yeast hexokinase P
II. In the model of glucokinase, the 10 helix is marked in red in
the “complex” (A) and “free” (B) conformation. In the model of
yeast hexokinase P II, the 10 helix is marked in blue (C).
Glucokinase and yeast hexokinase P II structure coordinates
were obtained from the Research Collaboratory for Structural
Bioinformatics Data Bank (36,37). The structural models were
generated using the Vector NTI Suite program 3D Molecule
Viewer (InforMax).
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higher glucokinase-GRP interaction than the single
changes of asparagine and leucine, indicating a synergistic
role of these two residues in the modulation of the
GRP-binding affinity. Interestingly, the N350/L355 motif is
accessible in both the closed and super-open conforma-
tion of glucokinase, but presentation of these residues
appears different. N350 and L355 are located in the 	10
helix of glucokinase, a structure that has a low homology
with the other enzymes of the hexokinase family (35,37).
In addition, asparagine N350 exists exclusively in the
glucokinase sequence.
While the conformation of the 	10 helix in the closed
form (Fig. 6A) appears similar to the corresponding con-
formation of yeast hexokinase II (Fig. 6C), the helical
structure formed by the amino acid residues 344–355 is
clearly exposed in the super-open conformation of glu-
cokinase (Fig. 6B). Therefore, the glucokinase 	10 helix
may play an important role for GRP recognition and
modulation of glucokinase-GRP binding. While in the
super-open conformation, the glucokinase-GRP complex
is formed through an interaction with the glucokinase
hinge region, the 	10 helix may be relevant for complex
stabilization. This assumption is supported by the fact that
the N350Y/L355R glucokinase mutant showed a signifi-
cantly higher nuclear-to-cytoplasmic glucokinase ratio in
primary hepatocytes than wild-type glucokinase at both 5
and 20 mmol/l glucose. The nuclear-to-cytoplasmic glu-
cokinase ratio of the wild-type protein at both glucose
concentrations was comparable with glucokinase distribu-
tion data obtained from liver samples of starved and
2-h–refed rats, as well as with data upon primary hepato-
cytes at high and low glucose (42–44). A nuclear accumu-
lation of glucokinase, which was comparable to that of the
N350Y/L355R mutant protein, has been described only
after an excessive overexpression of GRP in hepatocytes
(45). Interestingly, a lack of glucokinase translocation in
response to high glucose concentrations has recently been
reported for Zucker diabetic fatty rats, indicating a func-
tional role in the pathogenesis of type 2 diabetes (46).
Mutations within the 	10 helix may be the underlying
mechanism for this defect. While in COS-1 cells the
cellular distribution of the glucokinase single mutants
N350Y and L355R was comparable to that of wild-type
glucokinase, the double mutation showed an additive
effect with strong nuclear localization both at high and low
glucose concentrations. This argues in favor of a func-
tional role of the asparagine-leucine motif for the confor-
mation of the 	10 helix that results in a high binding
affinity for GRP, a concomitant nuclear translocation of
glucokinase, and ultimately a reduced glucose phosphor-
ylation activity in the cytoplasmic compartment.
The functional relevance of the glucokinase-GRP inter-
action and the metabolic impact of the shuttling of glu-
cokinase between the cytoplasmic and nuclear compartment
has been convincingly demonstrated in GRP knockout mice
with impaired glucose tolerance (47) and by glucose infu-
sion in rats (19). In the present study, we identified the
L58/N204 and the L355/N350 leucine-asparagine motifs as
functional elements of the glucokinase protein that confer
interaction with the GRP and the nuclear shuttling of
glucokinase. In particular, the L355/N350 motif may mod-
ulate the strength of binding to the GRP. Thus, the
glucokinase mutant proteins generated in the present
study may be useful tools to analyze the molecular aspects
and the dynamics of glucokinase translocation in hepato-
cytes by live-cell–imaging techniques. Glucokinase mu-
tants with different binding affinities for GRP will help to
clarify the mechanism of nuclear export in response to
changes of the glucose and fructose concentrations, an
issue that is currently a matter of investigation in various
experimental approaches (20,22,43,46).
Recently, different small chemical compounds have
been described that are able to activate glucokinase
(36,48–50). While only some of these glucokinase activa-
tors increase the Vmax of glucokinase (36,48,50), all of
them decrease the S0.5 of the enzyme for the substrate
glucose. The effect on the glucokinase-GRP interaction has
been analyzed for two different glucokinase activators.
The affinity of glucokinase for GRP was not affected by
GKA1 (49), whereas RO-28-1675 reversed the inhibitory
action of GRP (48). The future development of com-
pounds, which modulate the glucokinase-GRP–binding
affinity, will open the perspective of a selective activation
of liver glucokinase, as there is so far only marginal
evidence for a physiological role of GRP in pancreatic
-cells (10,29). The activation of glucose metabolism in
liver represents a promising therapeutic concept to coun-
teract the imbalance between glycolysis, glycogen synthe-
sis, and hepatic glucose production in type 2 diabetes.
Perspectively, the described glucokinase mutant proteins
may help to elucidate the molecular mechanisms of glu-
cokinase activators within the process of GRP binding and
glucokinase translocation.
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